



Aurobindo Pharma receives tentative approval for Emtricitabine / Tenofovir Disproxil Fumarate Tablets

Aurobindo Pharma Limited is pleased to announce that it is one of the first generics company to have received the tentative approval to manufacture and market its anti-AIDS combination drug Emtricitabine / Tenofovir Disproxil Fumarate Tablets 200mg/300mg from the US Food & Drug Administration (USFDA).

Emtricitabine / Tenofovir Disproxil Fumarate Tablets 200mg/300mg is the generic equivalent of Gilead Sciences Inc's Truvada® tablets 200mg/300mg and falls under the Anti-Retroviral (ARV) segment. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. This ANDA was reviewed under the expedited provisions of the President's Emergency Plan for AIDS relief (PEPFAR).

Aurobindo now has a total of 95 ANDA approvals (68 Final approvals and 27 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com